Evidence map›Paper›PMID 26424589›Full record

Trial reportJournal of diabetes and its complications

Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial.

Candida J Rebello, Jeffrey Burton, Mark Heiman, Frank L Greenway

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 5 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Impacts of Lifestyle and Microbiota-Targeted Interventions for Overweight and Obesity on the Human Gut Microbiome: A Systematic Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Microbiota revolution: How gut microbes regulate our lives.World journal of gastroenterology · 2023
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Candida J RebelloPennington Biomedical Research Center, Louisiana State University System, 6400, Perkins Road Baton Rouge, LA 70808, USA; School of Nutrition and Food Sciences, Louisiana State University, Baton Rouge, LA 70803, USA. Electronic address: Candida.Rebello@pbrc.edu.
Jeffrey BurtonPennington Biomedical Research Center, Louisiana State University System, 6400, Perkins Road Baton Rouge, LA 70808, USA. Electronic address: Jeff.Burton@pbrc.edu.
Mark HeimanMicroBiome Therapeutics LLC, 1316 Jefferson Ave., New Orleans, LA 70115, USA. Electronic address: mheiman@mbiome.com.
Frank L GreenwayPennington Biomedical Research Center, Louisiana State University System, 6400, Perkins Road Baton Rouge, LA 70808, USA. Electronic address: Frank.Greenway@pbrc.edu.
Louisiana State University System · USLouisiana State University · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2005 to 2026
$26.5M
NIDDK NIH HHS 2P30DK072476NIDDK NIH HHS P30 DK072476NIGMS NIH HHS 1 U54 GM104940NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

objectiveThe objective of this study was to examine the effects of a gastrointestinal microbiome modulator (GIMM) containing inulin, β-glucan, blueberry anthocyanins, and blueberry polyphenols on metabolic parameters, fecal markers of gut microbiota, and satiety. DESIGN AND

methodsThirty overweight or obese individuals aged 18 to 70years, were enrolled in a randomized controlled trial. Participants consumed the test product or placebo daily for four weeks. Stool samples were collected and blood was drawn at baseline and week four for assessments of gut microbiota, satiety hormones, glucose control, and lipid measures. Subjective satiety was assessed weekly. Linear models were used to compare differences from baseline to week four.

resultsGIMM consumption improved blood glucose tolerance (p=0.008), and increased satiety (p=0.03). There were no statistically significant differences in insulin sensitivity, fecal markers of gut microbiota, plasma satiety hormones, or serum lipid concentrations between the groups. However, plasma satiety hormones and fecal short chain fatty acid concentrations increased in the test group compared to the placebo.

conclusionsGIMM consumption for four weeks, increases satiety, and improves glucose tolerance possibly through insulin-independent pathways.

Indexed as

Dietary SupplementsGastrointestinal MicrobiomeAppetite DepressantsAvenabeta-GlucansBiomarkersBlueberry PlantsBody Mass IndexDietary FiberFecesFemaleFlavonoidsFruitGlucose IntoleranceHumansInsulin ResistanceAppetite Depressantsbeta-GlucansBiomarkersDietary FiberFlavonoidsInulinBlueberryGlucose toleranceInulinMicrobiotaSatietyβ-Glucan

Identifiers

PMID26424589
PMCPMC4656110
OpenAlexW1641336449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.